AR106180A2 - A-AMINOCARBOXYAMIDE COMPOUND THAT IS 5- (4 - {[(2-FLUOROPHENYL) METHYL] OXI} PHENYL) PROLINAMIDE - Google Patents

A-AMINOCARBOXYAMIDE COMPOUND THAT IS 5- (4 - {[(2-FLUOROPHENYL) METHYL] OXI} PHENYL) PROLINAMIDE

Info

Publication number
AR106180A2
AR106180A2 ARP160102963A ARP160102963A AR106180A2 AR 106180 A2 AR106180 A2 AR 106180A2 AR P160102963 A ARP160102963 A AR P160102963A AR P160102963 A ARP160102963 A AR P160102963A AR 106180 A2 AR106180 A2 AR 106180A2
Authority
AR
Argentina
Prior art keywords
compound
prolinamide
fluorophenyl
phenyl
methyl
Prior art date
Application number
ARP160102963A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR106180A2 publication Critical patent/AR106180A2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuesto de a-aminocarboxiamida que es 5-(4-{[(2-fluorofenil)metil]oxi}fenil)prolinamida de fórmula (1), ó un compuesto de fórmula (2), o su sal farmacéuticamente aceptable, solvato o profármaco, como ser el hidrocloruro. Dicho compuesto en forma cristalina. Composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento para tratar o prevenir una enfermedad o trastorno mediados por la modulación de los canales de sodio con apertura por voltaje (“voltage-gated”), dependientes del uso, como ser depresión o trastorno del estado emocional, trastorno bipolar o relacionado con sustancias. Proceso para preparar dicho compuesto.A-aminocarboxamide compound which is 5- (4 - {[(2-fluorophenyl) methyl] oxy} phenyl) prolinamide of formula (1), or a compound of formula (2), or its pharmaceutically acceptable salt, solvate or prodrug , such as hydrochloride. Said compound in crystalline form. Pharmaceutical composition that comprises it and its use for the manufacture of a medicine to treat or prevent a disease or disorder mediated by the modulation of the voltage-gated sodium channels, depending on the use, such as depression or emotional state disorder, bipolar or substance-related disorder. Process to prepare said compound.

ARP160102963A 2005-10-10 2016-09-28 A-AMINOCARBOXYAMIDE COMPOUND THAT IS 5- (4 - {[(2-FLUOROPHENYL) METHYL] OXI} PHENYL) PROLINAMIDE AR106180A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds

Publications (1)

Publication Number Publication Date
AR106180A2 true AR106180A2 (en) 2017-12-20

Family

ID=35430120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102963A AR106180A2 (en) 2005-10-10 2016-09-28 A-AMINOCARBOXYAMIDE COMPOUND THAT IS 5- (4 - {[(2-FLUOROPHENYL) METHYL] OXI} PHENYL) PROLINAMIDE

Country Status (5)

Country Link
CN (1) CN101326163B (en)
AR (1) AR106180A2 (en)
GB (1) GB0520581D0 (en)
UA (1) UA93887C2 (en)
ZA (1) ZA200802879B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US9676757B2 (en) * 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
CN112812048B (en) * 2021-01-20 2022-08-26 北京蓝博特科技有限公司 Preparation method of sodium ion channel retarder CNV1014802 hydrochloride form

Also Published As

Publication number Publication date
UA93887C2 (en) 2011-03-25
CN101326163B (en) 2011-03-09
CN101326163A (en) 2008-12-17
GB0520581D0 (en) 2005-11-16
ZA200802879B (en) 2010-06-30

Similar Documents

Publication Publication Date Title
AR056575A1 (en) COMPOSITE OF (ALPHA) -AMINOCARBOXYAMIDE THAT IS 5- (4 - [[(2-FLUOROPHENYL) METHYL] OXI] PHENYL) PROLINAMIDE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS TO PREPARE IT
AR053162A1 (en) COMPOUND 5 - OXO - REPLACED PIRROLIDIN, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF GLAUCOMA.
AR047992A1 (en) DIAMINOPIRIMIDINS AS ANTAGONISTS OF P2X3 AND P2X2 / 3
GT200600163A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
CO5640076A2 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY AN IBAT INHIBITOR FOR THE TREATMENT OR PROFILAXIS OF THE CONSTIPATION
CO6160236A2 (en) QUINASE INHIBITOR
ECSP055867A (en) PIRROLOPIRIMIDINE DERIVATIVES
AR048336A1 (en) HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
ECSP055774A (en) NEW MEDICATION FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
ECSP066312A (en) PIRIDILO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
CL2011000589A1 (en) Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
AR058780A1 (en) IMIDAZOPIRAZINAS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
EA200900155A1 (en) MODULATORS OF PHARMACOKINETIC PROPERTIES OF MEDICINES
ECSP066950A (en) ADRENOCEPTOR-BETA2 GLICOPIRROLATE AND AGONIST COMBINATIONS
ECSP088973A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3)
DK1689721T3 (en) Aminopyrazole derivatives as GSK-3 inhibitors
ECSP088283A (en) PIRIDINE COMPOUNDS 5- (PHENYLISOXAZOLILETOXI) -TRIAZOL- 3-ILO SUBSTITUTED FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
AR058293A1 (en) PROFARMATIC SALTS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIRIMIDIN-5-CARBONIL) -2-METOXI-PHENIL] -3- (2,4- DICLOR-PHENYL)
UY30426A1 (en) SUBSTITUTED DERIVATIVES OF 3- (4-METOXI-PHENYL) -3H-ISOINDOL-1-ILLUMIN TRIFLUOROACETATE, ITS SALTS OR SOLVATOS PHARMACEUTICALLY ACCEPTABLE, PHARMACEUTICAL FORMULATIONS AND APPLICATIONS.
UY29085A1 (en) PIRIMIDINE DERIVATIVES 4-SULFONAMID SUBSTITUTED, INTERMEDIATE COMPOUNDS FOR PREPARATION, PREPARATION PROCEDURES, MEDICINAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
EA201000643A1 (en) SUBSTITUTED PRODUCTION OF ETHYLENEDIAMIN FOR THE TREATMENT OF MYCOBACTERIAL DISEASES AND PHARMACEUTICAL COMPOSITION ON ITS BASIS
CL2009000241A1 (en) Compounds derived from 5- (2-morpholin-4-yl-7h-pyrrolo [2,3-d] pyrimidin-4-yl) pyrimidin-2-ylamine; Preparation process; pharmaceutical composition; and use of the compounds to treat or prevent a proliferative disease such as cancer.
ECSP088099A (en) NEW DERIVATIVES OF 2-AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES

Legal Events

Date Code Title Description
FC Refusal